AI Article Synopsis

  • Prostate-specific membrane antigen (PSMA) PET scans are used to assess treatment responses in metastatic prostate cancer by measuring parameters like standardized uptake value (SUV) and PSMA-positive tumor volume (PSMA-TV), but calculating whole-body PSMA-TV can be time-consuming.
  • A study with 65 patients evaluated the effectiveness of using only a few of the hottest or largest lesions to quantify changes in PSMA-TV and other related parameters, comparing these results with whole-body calculations and correlating them with serum prostate-specific antigen (PSA) levels.
  • Results indicated that in patients with metastatic hormone-sensitive prostate cancer, there were no significant differences in the calculated parameters; however, variations were noted in patients treated with taxanes and radiol

Article Abstract

(1) Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-derived parameters, such as the commonly used standardized uptake value (SUV) and PSMA-positive tumor volume (PSMA-TV), have been proposed for response assessment in metastatic prostate cancer (PCa) patients. However, the calculation of whole-body PSMA-TV remains a time-consuming procedure. We hypothesized that it may be possible to quantify changes in PSMA-TV by considering only a limited number of representative lesions. (2) Methods: Sixty-five patients classified into different disease stages were assessed by PSMA PET/CT for staging and restaging after therapy. Whole-body PSMA-TV and whole-body SUV were calculated. We then repeated this calculation only including the five or ten hottest or largest lesions. The corresponding serum levels of prostate-specific antigen (PSA) were also determined. The derived delta between baseline and follow-up values provided the following parameters: ΔSUV, ΔSUV, ΔSUV, ΔPSMA-TV, ΔPSMA-TV, ΔPSMA-TV, ΔPSA. Finally, we compared the findings from our whole-body segmentation with the results from our keyhole approach (focusing on a limited number of lesions) and correlated all values with the biochemical response (ΔPSA). (3) Results: Among patients with metastatic hormone-sensitive PCa (mHSPC), none showed a relevant deviation for ΔSUV/ΔSUV or ΔPSMA-TV/ΔPSMA-TV compared to ΔSUV and ΔPSMA-TV. For patients treated with taxanes, up to 6/21 (28.6%) showed clinically relevant deviations between ΔSUV and ΔSUV or ΔSUV, but only up to 2/21 (9.5%) patients showed clinically relevant deviations between ΔPSMA-TV and ΔPSMA-TV or ΔPSMA-TV. For patients treated with radioligand therapy (RLT), up to 5/28 (17.9%) showed clinically relevant deviations between ΔSUV and ΔSUV or ΔSUV, but only 1/28 (3.6%) patients showed clinically relevant deviations between ΔPSMA-TV and ΔPSMA-TV or ΔPSMA-TV. The highest correlations with ΔPSA were found for ΔPSMA-TV (r ≥ 0.59, ≤ 0.01), followed by ΔPSMA-TV (r ≥ 0.57, ≤ 0.01) and ΔPSMA-TV (r ≥ 0.53, ≤ 0.02) in all cohorts. ΔPSA only correlated with ΔSUV (r = 0.60, = 0.02) and with ΔSUV (r = 0.53, = 0.03) in the mHSPC cohort, as well as with ΔSUV (r = 0.51, = 0.01) in the RLT cohort. (4) Conclusion: Response assessment using PSMA-TV with a reduced number of lesions is feasible, and may allow for a simplified evaluation process for PSMA PET/CT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137844PMC
http://dx.doi.org/10.3390/biology11050660DOI Listing

Publication Analysis

Top Keywords

Δsuv Δsuv
24
Δpsma-tv Δpsma-tv
24
clinically relevant
16
relevant deviations
16
Δsuv
13
Δpsma-tv
13
response assessment
12
psma pet/ct
12
Δpsma-tv ≥
12
whole-body segmentation
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!